Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

SNSS 0.730 -0.055 (-7.01%)
price chart
Recent Broker Updates On Sunesis Pharmaceuticals, Inc. (SNSS)
Recently stock market analysts have updated their consensus ratings on shares of Sunesis Pharmaceuticals, Inc. (SNSS).
Sunesis Pharmaceuticals Inc. (SNSS) Hits New 52-week Low During February 03 ...
Sunesis Pharmaceuticals Inc. (SNSS) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $0.76, Sunesis Pharmaceuticals Inc. dropped to $0.70 for a new 52-week low. By the closing bell, the company's ...
Sunesis Pharmaceuticals Inc. (SNSS) Jumps 5.19% on February 04
Sunesis Pharmaceuticals Inc. (SNSS) was among the biggest gainers on the Russell 2000 for Thursday February 04 as the stock popped 5.19% to $0.77, representing a gain of $0.038 per share.
Stock Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Announces European ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for vosaroxin as a treatment for relapsed refractory acute myeloid leukemia (AML) in ...
Sunesis Pharmaceuticals Announces European Medicines Agency Validates ...  CNNMoney
Sunesis Pharmaceuticals Inc. (SNSS) Jumps 5.21% on January 20
Sunesis Pharmaceuticals Inc. (SNSS) was among the biggest gainers on the Russell 2000 for Wednesday January 20 as the stock popped 5.21% to $0.86, representing a gain of $0.0425 per share.
Company Update (NASDAQ:SNSS): Sunesis Pharmaceuticals, Inc. Announces Pricing ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the pricing of underwritten offerings of (i) 9,561,905 shares of its common stock at a price of $0.84 per share, and (ii) 20,200 shares of its non-voting Series B Convertible Preferred Stock ...
Sunesis Announces Pricing of $25 Million Offering of Securities  GlobeNewswire (press release)
FDA seeks more clinical evidence on Sunesis Pharma cancer drug
Sunesis Pharmaceuticals Inc said the U.S. Food and Drug Administration called for more clinical evidence before considering approval for its cancer drug, sending the company's shares down 60 percent in after-market trading.
Is This the End of Sunesis?  24/7 Wall St.
Sunesis Pharmaceuticals Announces Regulatory Update  GlobeNewswire (press release)
Cantor Fitzgerald Upgrades Sunesis Pharmaceuticals, Inc. (SNSS) to Buy
Sunesis Pharmaceuticals logo Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) was upgraded by equities researchers at Cantor Fitzgerald from a “hold” rating to a “buy” rating in a research report issued on Tuesday, The Fly reports.
Growth Equity Opportunities Fund, LLC Owns 9% Stake in Sunesis ...  Intercooler Financial
Sunesis Pharmaceuticals, Inc. Offers A Moderate Risk 80% Return On The Short ...
When biotech companies implode, they often do so in spectacular fashion. In the last year alone, we've seen Ariad Pharmaceuticals, Geron Corp., and Sarepta Therapeutics - just to name a few, post eye-popping single day losses following negative events ...
Related articles »  
Sunesis Pharmaceuticals, Inc. (SNSS) Stake Owned by Growth Equity ...
Sunesis Pharmaceuticals logo Growth Equity Opportunities Fund, LLC recently disclosed that they own 9% of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) in a Schedule 13D/A disclosure that was filed with the SEC on Thursday, January 7th. The investor ...
Sunesis Pharmaceuticals, Inc. (SNSS) Upgraded at Cantor Fitzgerald  Corvus Business Newswire
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Earnings Focus